TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis

ABSTRACT

Introduction: Psoriatic Arthritis (PsA) is a chronic inflammatory disease characterized by psoriasis, synovitis, enthesitis, spondylitis, and association with extra-articular manifestations and comorbidities. Treatment of PsA dramatically changed since the introduction of anti-TNF drugs which have shown to reduce the symptoms and signs of the disease and slow the radiographic progression. Despite the introduction of new molecules with different mechanisms of action, the role of anti-TNF in the treatment of all disease manifestations of this intriguing disease is still central.

Areas covered: The aim of this paper is to review the role of anti-TNF drugs in the treatment of different disease domains in PsA (peripheral and axial joints, skin, enthesis, patient’s reported outcomes, extra-articular manifestations), reporting data from randomized clinical trials and observational studies. An extensive literature search was performed on PubMed, with no limits or filters. The following search terms were used: ‘anti-TNF’, ‘Psoriatic Arthritis’.

Expert opinion: Despite the emergence of different new treatments, anti-TNF therapy remains central in the management of all disease domains in PsA patients.

KEYWORDS:

• Psoriatic arthritis
• anti-TNF
• clinical assessment
• clinical targets

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Article Highlights

• Psoriatic arthritis is a potentially disabling chronic inflammatory disease with both articular and extra-articular manifestations.

• Anti-TNF therapy is still considered central in the treatment of PsA.

• Efficacy and effectiveness of anti-TNF therapy was proven in all disease manifestations of PsA, including peripheral arthritis, axial disease, enthesitis, dactylitis, skin, and extra-articular manifestations.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

*of interest

** of considerable interest: the articles provide the evidences of the efficacy of the different anti-TNF in PsA

Additional information

Funding

This paper was not funded.